FDA Opens Comment Period on GenAI Device Regulation - Medical Device and Diagnostic industry
Reported by Medical Device and Diagnostic industry · all stories from mddionline.com
Editorial digest
The U.S. Food and Drug Administration has opened a period for public comments regarding the regulation of generative artificial intelligence in medical devices.
Digests are written in our own words from the publisher's headline — we never reproduce article text. Read the original for the full reporting.
Read the full story at Medical Device and Diagnostic industry →More like this
Other stories our editors tagged with the same themes.
- Trusted health newsroom8/20/2026
FDA weighs regulatory approach for genAI medical devices - MobiHealthNews
The FDA is deliberating its regulatory strategy for generative AI medical devices.
- Reputable trade press8/20/2026
FDA considers ‘competency-based’ evaluations for GenAI-enabled medical devices - MassDevice
The FDA is considering 'competency-based' evaluations for generative AI medical devices.
- Trusted health newsroom8/19/2026
FDA seeks feedback on generative AI regulations - MedTech Dive
The FDA is soliciting public input on regulating generative AI technologies.
- Trusted health newsroom8/24/2026
STAT+: FDA digital health leader promises generative AI regulatory guidance is coming
FDA digital health head confirms generative AI regulatory guidelines are in development.
- Trusted health newsroom8/18/2026
FDA considering doctor-like assessment for AI-enabled devices - Axios
The FDA is considering a doctor-like assessment method for AI-enabled medical devices.
- Reputable trade press8/20/2026
FDA-cleared medical AI rarely tested for real-world benefits - News-Medical
FDA-cleared medical AI often lacks real-world benefit testing.